Presentation is loading. Please wait.

Presentation is loading. Please wait.

A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase.

Published byBernhard Gerhardt Modified over 5 years ago

Similar presentations

Presentation on theme: "A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase."— Presentation transcript:

1 A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase (ALDH) inhibitor diethylaminobenzaldehyde (DEAB), as a negative control to set the gate for ALDHhi cells, considered as TIC. (A) Negative control ES2 control. (B) ALDHhi ES2 control cells. (C) Negative control, ES2 PD-L1lo clone 1. (D) ALDHhi ES2 PD-L1lo clone 1 cells. (E) Negative control, ES2 PD-L1lo clone 2. (F) ALDHhi ES2 PD-L1lo clone 2 cells.

Download ppt "A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase."

Similar presentations

Fig. 4-1, p. 107. Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.
P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.
Fig. 11-1, p. 359. p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.
Table 6-1, p. 161. Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.
P. 192. Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.
Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.
Investigating the effects of human aldehyde dehydrogenase on vaccinia virus replication in breast cancer stem cells Mazin Elsarrag BNFO 300 12/4/2014.

Investigating the effects of human aldehyde dehydrogenase on vaccinia virus replication in breast cancer stem cells Mazin Elsarrag BNFO /4/2014.
SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.
CD44 PD-L1 FSC Human/Mouse Stromal Markers FSC DAPI FSC SSC FSC-W FSC-H SSC-W SSC-H Live cells Tumor cells CD44 - CD44 + Supplementary Figure S1. Gating.

CD44 PD-L1 FSC Human/Mouse Stromal Markers FSC DAPI FSC SSC FSC-W FSC-H SSC-W SSC-H Live cells Tumor cells CD44 - CD44 + Supplementary Figure S1. Gating.
CD8 CD4 IgM B220 ThymusA. C.BM D. LN CD4 CD8 CD43 B220 IgM Spleen counts B220 IgD E. F. Kim et al._Fig. S1. PIDD +/+PIDD -/- Spleen CD44 CD25 Gated on.

CD8 CD4 IgM B220 ThymusA. C.BM D. LN CD4 CD8 CD43 B220 IgM Spleen counts B220 IgD E. F. Kim et al._Fig. S1. PIDD +/+PIDD -/- Spleen CD44 CD25 Gated on.
Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.
A B Pax8 CK7 CA125 HE4 HE xenograft tumor primary #20 bright phase HE

A B Pax8 CK7 CA125 HE4 HE xenograft tumor primary #20 bright phase HE
 (1) recombinant DNA technology or DNA cloning,  (2) reproductive cloning  (3) therapeutic cloning.

 (1) recombinant DNA technology or DNA cloning,  (2) reproductive cloning  (3) therapeutic cloning.
Generation of Novel Thyroid Cancer Stem-Like Cell Clones

Generation of Novel Thyroid Cancer Stem-Like Cell Clones
Treatment with ipilimumab

Treatment with ipilimumab
Supplementary figures

Supplementary figures
advanced lung adenocarcinoma subtype

advanced lung adenocarcinoma subtype
Supplementary Figures S1 to S36

Supplementary Figures S1 to S36
Expression of stem cell markers in oral cavity and oropharynx squamous cell carcinoma  Flávia Paiva Prudente de Moraes, MD, Silvia Vanessa Lourenço, PhD,

Expression of stem cell markers in oral cavity and oropharynx squamous cell carcinoma  Flávia Paiva Prudente de Moraes, MD, Silvia Vanessa Lourenço, PhD,
A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS

A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS

Similar presentations

Ads by Google